Wallace 1978.

Methods	Randomised Phase II trial September 1974 to June 1976
Participants	326 women with advanced, recurrent or persistent squamous cell cervical cancer not suitable for surgery or radiotherapy
Interventions	Arm 1: adriamycin 60 mg/m2 iv q21 Arm 2: adriamycin 60 mg/m2 iv, vincristine 1.5 mg/m2 iv q21 Arm 3: adriamycin 60 mg/m2 iv, cyclophosphamide 500 mg/m2 iv q21
Outcomes	OS PFS Response rates Toxicity (WHO)
Notes	65 patients ineligible (more than half for wrong histological subtype, remainder because of wrong primary, 2nd primary, elevated urea or creatinine, poor risk at entry or no evidence of progression after previous treatment; breakdown of numbers not given). Further 69 patients deemed to be not evaluable (inadequate data collection, therapy not initiated, insufficient follow‐up after first course, improper randomisation, clerical errors and others; no specific breakdown in numbers)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Low risk	Closed envelope technique
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	High risk	65 patients ineligible and further 69 patients deemed to be not evaluable balanced across groups
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes